ES2097100T3 - Uso de la relaxina como analgesico y paliativo contra el dolor irreducible. - Google Patents

Uso de la relaxina como analgesico y paliativo contra el dolor irreducible.

Info

Publication number
ES2097100T3
ES2097100T3 ES94930479T ES94930479T ES2097100T3 ES 2097100 T3 ES2097100 T3 ES 2097100T3 ES 94930479 T ES94930479 T ES 94930479T ES 94930479 T ES94930479 T ES 94930479T ES 2097100 T3 ES2097100 T3 ES 2097100T3
Authority
ES
Spain
Prior art keywords
relaxin
pain
irreducible
palliative
analgesic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94930479T
Other languages
English (en)
Other versions
ES2097100T1 (es
Inventor
Brian Seed
John C Seed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of ES2097100T1 publication Critical patent/ES2097100T1/es
Application granted granted Critical
Publication of ES2097100T3 publication Critical patent/ES2097100T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE EXPONE EL USO DE RELAXINA EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL DOLOR.TAMBIEN SE EXPONE UN METODO PARA REDUCIR EL DOLOR EN UN MAMIFERO QUE IMPLICA LA ADMINISTRACION DE RELAXINA AL MISMO.
ES94930479T 1993-09-29 1994-09-26 Uso de la relaxina como analgesico y paliativo contra el dolor irreducible. Expired - Lifetime ES2097100T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/128,912 US5656592A (en) 1993-09-29 1993-09-29 Use of relaxin as an analgesic and palliative for intractable pain

Publications (2)

Publication Number Publication Date
ES2097100T1 ES2097100T1 (es) 1997-04-01
ES2097100T3 true ES2097100T3 (es) 2002-08-01

Family

ID=22437587

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94930479T Expired - Lifetime ES2097100T3 (es) 1993-09-29 1994-09-26 Uso de la relaxina como analgesico y paliativo contra el dolor irreducible.

Country Status (10)

Country Link
US (1) US5656592A (es)
EP (1) EP0721467B1 (es)
JP (1) JPH09503208A (es)
KR (1) KR960704933A (es)
AT (1) ATE211920T1 (es)
AU (1) AU7958694A (es)
DE (2) DE721467T1 (es)
ES (1) ES2097100T3 (es)
PT (1) PT721467E (es)
WO (1) WO1995009184A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952296A (en) * 1993-07-27 1999-09-14 Bigazzi; Mario Method of using relaxin as therapeutic or preventing agent
US5612051A (en) * 1995-11-17 1997-03-18 Yue; Samuel K. Method of treating involuntary muscle dysfunction with relaxin hormone
US6719977B1 (en) 1998-02-12 2004-04-13 The General Hospital Corporation Methods to potentiate cancer therapies
WO1999040929A1 (en) * 1998-02-12 1999-08-19 The General Hospital Corporation Methods to potentiate cancer therapies
EP1862981B1 (en) * 1998-08-14 2014-12-31 3M Innovative Properties Company Applications for radio frequency identification systems
CN100492388C (zh) 1998-08-14 2009-05-27 3M创新有限公司 射频识别系统应用
US6251863B1 (en) 1998-09-08 2001-06-26 Samuel K. Yue Method of preventing and treating symptoms of aging and neurodegenerative dysfunctions with relaxin
US6984128B2 (en) * 2002-11-01 2006-01-10 Bas Medical, Inc. Methods for enabling and stabilizing tooth movement
CN104888182A (zh) * 2015-07-07 2015-09-09 韩军 一种治疗产后腹痛的中药制剂及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656249A (en) * 1982-06-10 1987-04-07 Howard Florey Institute Of Experimental Physiology And Medicine Peptides with relaxin activity
US5145962A (en) * 1982-08-12 1992-09-08 Howard Florey Institute Of Experimental Physiology And Medicine Human pro relaxin polypeptides
US5179195A (en) * 1982-12-13 1993-01-12 Howard Florey Institute Of Experimental Physiology And Medicine Human relaxin polypeptides

Also Published As

Publication number Publication date
DE69429664D1 (de) 2002-02-21
DE69429664T2 (de) 2002-08-14
PT721467E (pt) 2002-05-31
JPH09503208A (ja) 1997-03-31
EP0721467A4 (en) 1998-04-22
ATE211920T1 (de) 2002-02-15
AU7958694A (en) 1995-04-18
EP0721467B1 (en) 2002-01-16
KR960704933A (ko) 1996-10-09
EP0721467A1 (en) 1996-07-17
WO1995009184A1 (en) 1995-04-06
US5656592A (en) 1997-08-12
ES2097100T1 (es) 1997-04-01
DE721467T1 (de) 1997-06-26

Similar Documents

Publication Publication Date Title
DE69420419D1 (de) Hautpermeabilitaetserhöher bestehend aus monoglycerid/laktat estern
MY109727A (en) Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals
MA22677A1 (fr) Compositions cosmetiques en gels
AR240399A1 (es) Dispositivo suministrador para administrar una formulacion de agente beneficioso a un ambiente de uso.
FI940383A7 (fi) Menetelmä ja laite H2-ilma-höyryseoksen sisältämän vedyn rekombinaatiota ja/tai sytyttämistä varten erityisesti ydinvoimalaitosten käyttöön
ES2097100T3 (es) Uso de la relaxina como analgesico y paliativo contra el dolor irreducible.
ES8801578A1 (es) Un procedimiento para preparar una formulacion en emulsion de anfotericina b adecuada para administracion parenteral.
KR960012179A (ko) 전계 방출 디스플레이에서 접합 누설 방지하는 방법
TR199800415T1 (en) Farmas�tik form�lasyon.
PT904067E (pt) Dextrometorfan como agente antitussico administrado transdermicamente
NO962655L (no) Deutrerte virkestoffer i transdermal applikasjon
WO1987001282A3 (en) Method and composition for providing sustained opioid antagonism
ES2090167T3 (es) Uso topico de glicosaminoglicanos en la prevencion y el tratamiento de enfermedades que afectan al tracto vaginal cervical.
FI904144A0 (fi) Etanolipolttoaine ja sen käyttö dieselpolttoaineena
BR8903219A (pt) Composicoes e formulacoes de aditivos bem como sua utilizacao em combustivel
ITUD930070A1 (it) Mobile per sedersi idoneo ad essere trasformato in mobile per sdraiarsi
AU4650899A (en) Kit of drug-containing preparation to be prepared before using and resolvent therefor
AU590365B2 (en) Azapropazone prevention of post-ischemic tissue damage
IT8835528V0 (it) Siringa con ago incorporato automaticamente rientrante dopo l'uso nel cilindro della siringa stessa per evitare pericoli di punture ed infezioni
IT8464451U1 (it) Dispositivo atto ad effettuare massaggi ad uso terapeutico ed estetico
JPS53149441A (en) Cosmetic device
SE403700B (sv) For rullstolsbundna, atminstone i arm- och axelparti forlamade personer avsett armstod
ITMI912511A0 (it) Uso di formulazioni liposomiali contenenti papaverina nel trattamento della impotenza maschile
MX9700626A (es) USO DE AZASPIRANOS EN LA REPARACIaN DE COMPOSICIONES PARA TRATAR INFECCIONES OPORTUNISTAS.
LV10257A (lv) Jauni pilokarpina atvasinajumi un to iegusanas metode

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 721467

Country of ref document: ES